The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
The Novel Histologic International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society Classification System of Lung Adenocarcinoma Is a Stage-Independent Predictor of Survival
Abstract
Purpose: Our aim was to analyze and validate the prognostic impact of the novel International Association for the Study of Lung Cancer (IASLC)/American Thoracic Society (ATS)/European Respiratory Society (ERS) proposal for an architectural classification of invasive pulmonary adenocarcinomas (ADCs) across all tumor stages. Patients and Methods: The architectural pattern of a large cohort of 500 patients with resected ADCs (stages I to IV) was retrospectively analyzed in 5% increments and classified according to their predominant architecture (lepidic, acinar, solid, papillary, or micropapillary), as proposed by the IASLC/ATS/ERS. Subsequently, histomorphologic data were correlated with clinical data, adjuvant therapy, and patient outcome. Results: Overall survival differed significantly between lepidic (78.5 months), acinar (67.3 months), solid (58.1 months), papillary (48.9 months), and micropapillary (44.9 months) predominant ADCs (P = .007). When patterns were lumped into groups, this resulted in even more pronounced differences in survival (pattern group 1, 78.5 months; group 2, 67.3 months; group 3, 57.2 months; P = .001). Comparable differences were observed for overall, disease-specific, and disease-free survival. Pattern and pattern groups were stage- and therapy-independent prognosticators for all three survival parameters. Survival differences according to patterns were influenced by adjuvant chemoradiotherapy; in particular, solid-predominant tumors had an improved prognosis with adjuvant radiotherapy. The predominant pattern was tightly linked to the risk of developing nodal metastases (P < .001). Conclusion: Besides all recent molecular progress, architectural grading of pulmonary ADCs according to the novel IASLC/ATS/ERS scheme is a rapid, straightforward, and efficient discriminator for patient prognosis and may support patient stratification for adjuvant chemoradiotherapy. It should be part of an integrated clinical, morphologic, and molecular subtyping to further improve ADC treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jemal, A., Siegel, R., Xu, J., & Ward, E. (2010) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20073 · Cited by 12,596
Comparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung Cancer
Schiller, J. H., Harrington, D., Belani, C. P., Langer, C., Sandler, A., Krook, J., Zhu, J., & Johnson, D. H. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011954 · Cited by 4,955
Travis, W. D., Brambilla, E., Noguchi, M., Nicholson, A. G., Geisinger, K. R., Yatabe, Y., Beer, D. G., Powell, C. A., Riely, G. J., Van Schil, P. E., et al. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318206a221 · Cited by 4,792
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
Kwak, E. L., Bang, Y.-J., Camidge, D. R., Shaw, A. T., Solomon, B., Maki, R. G., Ou, S.-H. I., Dezube, B. J., Jänne, P. A., Costa, D. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1006448 · Cited by 4,446
COMPARISON OF FOUR CHEMOTHERAPY REGIMENS FOR ADVANCED NON-SMALL-CELL LUNG CANCER
Chiller, J. O. H. S., Arrington, D. A. H., Elani, C. H. P. B., Anger, C., Andler, A. L. S., Rook, J. A. K., Hu, J., & Ohnson, D. A. H. J. (2002) · Cited by 3,730
Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer
Rosell, R., Moran, T., Queralt, C., Porta, R., Cardenal, F., Camps, C., Majem, M., Lopez-Vivanco, G., Isla, D., Provencio, M., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0904554 · Cited by 2,373
Gleason, D. F., Mellinger, G. T., & The Veterans Administration Cooperative Urological Research Group Members of this group areS0022534717598894-57c401330b4195dbd1713587ed540477 Lino J. Arduino Veterans Administration Center (VAC), D. M. (1974) · Journal of Urology · doi:10.1016/s0022-5347(17)59889-4 · Cited by 2,214
Small adenocarcinoma of the lung. Histologic characteristics and prognosis
Noguchi, M., Morikawa, A., Kawasaki, M., Matsuno, Y., Yamada, T., Hirohashi, S., Kondo, H., & Shimosato, Y. (1995) · Cancer · doi:10.1002/1097-0142(19950615)75:12<2844::aid-cncr2820751209>3.0.co;2-# · Cited by 1,134
Yoshizawa, A., Motoi, N., Riely, G. J., Sima, C. S., Gerald, W. L., Kris, M. G., Park, B. J., Rusch, V. W., & Travis, W. D. (2011) · Modern Pathology · doi:10.1038/modpathol.2010.232 · Cited by 976
Russell, P. A., Wainer, Z., Wright, G. M., Daniels, M., Conron, M., & Williams, R. A. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318221f701 · Cited by 624
Motoi, N., Szoke, J., Riely, G. J., Seshan, V. E., Kris, M. G., Rusch, V. W., Gerald, W. L., & Travis, W. D. (2008) · American Journal of Surgical Pathology · doi:10.1097/pas.0b013e31815cb162 · Cited by 371
Sica, G., Yoshizawa, A., Sima, C. S., Azzoli, C. G., Downey, R. J., Rusch, V. W., Travis, W. D., & Moreira, A. L. (2010) · American Journal of Surgical Pathology · doi:10.1097/pas.0b013e3181e4ee32 · Cited by 325
The Evolving Role of Histology in the Management of Advanced Non–Small-Cell Lung Cancer
Langer, C. J., Besse, B., Gualberto, A., Brambilla, E., & Soria, J.-C. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.8126 · Cited by 300
Invasive Size is an Independent Predictor of Survival in Pulmonary Adenocarcinoma
Borczuk, A. C., Qian, F., Kazeros, A., Eleazar, J., Assaad, A., Sonett, J. R., Ginsburg, M., Gorenstein, L., & Powell, C. A. (2009) · American Journal of Surgical Pathology · doi:10.1097/pas.0b013e318190157c · Cited by 186
Crizotinib for EML4-ALK positive lung adenocarcinoma: a hope for the advanced disease?
Antoniu, S. A. (2011) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2011.550880 · Cited by 159
Histologic features are important prognostic indicators in early stages lung adenocarcinomas
Yim, J. H., Zhu, L., Chiriboga, L. A., Watson, H. N., Goldberg, J. D., & Moreira, A. L. (2006) · Modern Pathology · doi:10.1038/modpathol.3800734 · Cited by 147
Prognostic significance of grading in lung adenocarcinoma
Barletta, J. A., Yeap, B. Y., & Chirieac, L. R. (2009) · Cancer · doi:10.1002/cncr.24831 · Cited by 136
Riquet, M., Foucault, C., Berna, P., Assouad, J., Dujon, A., & Danel, C. J. (2006) · The Annals of Thoracic Surgery · doi:10.1016/j.athoracsur.2006.01.021 · Cited by 66
Systemic Therapy of Advanced Bronchioloalveolar Cell Carcinoma: Challenges and Opportunities
Miller, V. A., Hirsch, F. R., & Johnson, D. H. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.19.240 · Cited by 66
Prospects for molecular staging of non-small-cell lung cancer from genomic alterations
Tomaszek, S. C., Huebner, M., & Wigle, D. A. (2010) · Expert Review of Respiratory Medicine · doi:10.1586/ers.10.40 · Cited by 7
Cited by
The 2015 World Health Organization Classification of Lung Tumors
Travis, W. D., Brambilla, E., Nicholson, A. G., Yatabe, Y., Austin, J. H. M., Beasley, M. B., Chirieac, L. R., Dacic, S., Duhig, E., Flieder, D. B., et al. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000630 · Cited by 4,520
Postmus, P. E., Kerr, K. M., Oudkerk, M., Senan, S., Waller, D. A., Vansteenkiste, J., Escriu, C., & Peters, S. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx222 · Cited by 2,302
Yu, K.-H., Zhang, C., Berry, G. J., Altman, R. B., Ré, C., Rubin, D. L., & Snyder, M. (2016) · Nature Communications · doi:10.1038/ncomms12474 · Cited by 972
Alberg, A. J., Brock, M. V., & Samet, J. M. (2016) · Murray and Nadel's Textbook of Respiratory Medicine · doi:10.1016/b978-1-4557-3383-5.00052-x · Cited by 781
Travis, W. D., Asamura, H., Bankier, A. A., Beasley, M. B., Detterbeck, F., Flieder, D. B., Goo, J. M., MacMahon, H., Naidich, D., Nicholson, A. G., et al. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.03.025 · Cited by 722
Metadata
- Authors
- Warth, A., Muley, T., Meister, M., Stenzinger, A., Thomas, M., Schirmacher, P., Schnabel, P. A., Budczies, J., Hoffmann, H., & Weichert, W.
- Venue
- Journal of Clinical Oncology
- Published
- 2012-05-01
- Volume
- 30
- Issue
- 13
- Pages
- 1438-1446
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2163149604
- Cited by
- 692
- References
- 20
- FWCI
- 43.87
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.